FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

38 letters match. Newest first.

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  5. Ketamine Troche Store / www.ketaminetrochestore.com

    FDA warned online seller Ketamine Troche Store that its website sells unapproved, misbranded ketamine drugs without prescriptions.

    High risk
  6. Buy Keta Online / www.buyketaonline.com

    FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.

    High risk
  7. Ketamine Store / www.ketaminestore.org

    FDA warned website Ketamine Store for selling unapproved, misbranded ketamine liquid and compounded products online without prescriptions.

    High risk
  8. NativeMed LLC dba NativeMed

    FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  9. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low
  10. Glow Medispa, LLC dba Mint Med

    FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.

    Low
  11. D&H Medical Services

    FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

    Low
  12. Medica Weight Loss

    FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.

    Medium
  13. OrderlyMeds LLC dba OrderlyMeds

    FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.

    Low
  14. Joi and Blokes dba Joi + Blokes

    FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.

    Medium
  15. Clover Meds LLC dba Clover Meds

    Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.

    Medium
  16. Refills Health, LLC dba Refills Health

    FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.

    Medium
  17. Weightless Medical LLC dba WeightCare

    FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.

    Low
  18. Viv Health, Inc. dba VIV RX

    FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  19. Ivim Services LLC dba Ivim

    FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.

    Low
  20. MaxLife Technologies Inc. dba Maxlife

    FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.

    Medium
  21. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  22. MEDVi, LLC dba MEDVi

    FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.

    Medium
  23. Newman Clinic, PLLC dba Newman Clinic

    FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  24. Bliv Wellness LLC dba Bliv

    FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  25. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  26. Amazing Meds

    FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.

    High risk
  27. GenLabMeds

    GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.

    High risk
  28. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  29. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  30. ASN-LABS

    ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.

    High risk
  31. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  32. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  33. Carolina Infusion

    FDA warns Carolina Infusion over compounded drugs made without valid prescriptions and under insanitary conditions, including sterile products.

    High risk
  34. Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy

    FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.

    Medium
  35. Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine

    Advanced Nutriceuticals compounded sterile drugs without required prescriptions and under insanitary conditions, FDA says.

    High risk
  36. Matthew 7:25 Inc dba Thrive Pharmacy

    FDA says Thrive Pharmacy compounded drugs without valid prescriptions and released subpotent buprenorphine troches, making them adulterated and misbranded.

    High risk
  37. Walfer Corporation dba The Medicine Shoppe Pharmacy

    FDA warned The Medicine Shoppe Pharmacy in Port Charlotte, Florida, over insanitary compounding conditions, vermin, and drugs made without valid prescriptions.

    High risk
  38. Pharmaceutical Care Solutions dba Pharmacy Solutions

    FDA warns Pharmaceutical Care Solutions dba Pharmacy Solutions over compounded drugs made with ineligible bulk substances and lacking FDA approval.

    Medium